Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares)
-
Shares outstanding
-
239,647,920
-
Total 13F shares
-
53,756,642
-
Share change
-
+1,917,312
-
Total reported value
-
$5,723,406,583
-
Put/Call ratio
-
125%
-
Price per share
-
$106.47
-
Number of holders
-
256
-
Value change
-
+$241,987,238
-
Number of buys
-
114
-
Number of sells
-
132
Institutional Holders of BioNTech SE - Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (BNTX) as of Q2 2025
As of 30 Jun 2025,
BioNTech SE - Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (BNTX) was held by
256 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
53,756,642 shares.
The largest 10 holders included
FMR LLC, BAILLIE GIFFORD & CO, FLOSSBACH VON STORCH SE, PRIMECAP MANAGEMENT CO/CA/, Pfizer Inc, T. Rowe Price Investment Management, Inc., Temasek Holdings (Private) Ltd, BlackRock, Inc., BNP PARIBAS FINANCIAL MARKETS, and Capital International Investors.
This page lists
256
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.